Due to lack of product demand, 50 million doses of Covaxin set to expire early 2023

way2barak, Nov.6: Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin, are set to expire early next year as there are no takers owing to poor demand resulting in losses for the company.

Bharat Biotech has more than 200 million doses of Covaxin in bulk form and approximately 50 million doses in vials ready to use. Covaxin doses in vials are set to expire during early 2023. However, the quantum of loss that the Bharat Biotech would incur in the event of all the 50 million doses expiring next year is not known.

So far, 219.71 crore doses of Covid-19 vaccines, including Covaxin have been administered under the nationwide vaccination drive.